 CRANBURY, N.J., Sept. 27, 2021 GLOBE NEWSWIRE -- Rafael Pharmaceuticals, Inc. Rafael or the Company, a leader in the growing field of cancer metabolism-based therapeutics, announced that the Phase 1 clinical trial of CPI-613 devimistat in combination with hydroxychloroquine in patients with clear cell sarcoma is open for enrollment. The clinical trial will begin enrolling patients at City of Hope in Duarte, California, with other sites across the country to quickly follow. 